146 related articles for article (PubMed ID: 23645169)
1. Cellular immunotherapy for plasma cell myeloma.
Garfall AL; Vogl DT; Weiss BM; Stadtmauer EA
Bone Marrow Transplant; 2013 Nov; 48(11):1377-86. PubMed ID: 23645169
[TBL] [Abstract][Full Text] [Related]
2. Cellular and vaccine immunotherapy for multiple myeloma.
Garfall AL; Stadtmauer EA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):521-527. PubMed ID: 27913524
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of multiple myeloma: Current strategies and future prospects.
Allegra A; Penna G; Innao V; Greve B; Maisano V; Russo S; Musolino C
Crit Rev Oncol Hematol; 2015 Nov; 96(2):339-54. PubMed ID: 26123319
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
[TBL] [Abstract][Full Text] [Related]
5. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
Minnie SA; Hill GR
Front Immunol; 2021; 12():651288. PubMed ID: 33777050
[TBL] [Abstract][Full Text] [Related]
6. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
[TBL] [Abstract][Full Text] [Related]
7. Cellular immunotherapy for multiple myeloma.
Rosenblatt J; Avigan D
Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
[TBL] [Abstract][Full Text] [Related]
8. Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.
Maybury B; Cook G; Pratt G; Yong K; Ramasamy K
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1926-1937. PubMed ID: 27288955
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
Karp Leaf R; Cho HJ; Avigan D
Curr Hematol Malig Rep; 2015 Dec; 10(4):395-404. PubMed ID: 26338470
[TBL] [Abstract][Full Text] [Related]
10. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.
Rapoport AP; Stadtmauer EA; Aqui N; Vogl D; Chew A; Fang HB; Janofsky S; Yager K; Veloso E; Zheng Z; Milliron T; Westphal S; Cotte J; Huynh H; Cannon A; Yanovich S; Akpek G; Tan M; Virts K; Ruehle K; Harris C; Philip S; Vonderheide RH; Levine BL; June CH
Clin Cancer Res; 2009 Jul; 15(13):4499-507. PubMed ID: 19509133
[TBL] [Abstract][Full Text] [Related]
11. Cellular immunotherapy as a therapeutic approach in multiple myeloma.
Liegel J; Avigan D; Rosenblatt J
Expert Rev Hematol; 2018 Jul; 11(7):525-536. PubMed ID: 29856648
[TBL] [Abstract][Full Text] [Related]
12. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
13. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Fang HB; Cai L; Janofsky S; Chew A; Storek J; Akpek G; Badros A; Yanovich S; Tan MT; Veloso E; Pasetti MF; Cross A; Philip S; Murphy H; Bhagat R; Zheng Z; Milliron T; Cotte J; Cannon A; Levine BL; Vonderheide RH; June CH
Blood; 2011 Jan; 117(3):788-97. PubMed ID: 21030558
[TBL] [Abstract][Full Text] [Related]
15. Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.
Lendvai N; Cohen AD; Cho HJ
Bone Marrow Transplant; 2015 Jun; 50(6):770-80. PubMed ID: 25751647
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy.
Condomines M; Veyrune JL; Larroque M; Quittet P; Latry P; Lugagne C; Hertogh C; Kanouni T; Rossi JF; Klein B
J Immunol; 2010 Jan; 184(2):1079-84. PubMed ID: 19966210
[TBL] [Abstract][Full Text] [Related]
17. Drug-mediated and cellular immunotherapy in multiple myeloma.
Ritchie DS; Quach H; Fielding K; Neeson P
Immunotherapy; 2010 Mar; 2(2):243-55. PubMed ID: 20635931
[TBL] [Abstract][Full Text] [Related]
18. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
19. CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.
Smith E; Devlin SM; Kosuri S; Orlando E; Landau H; Lesokhin AM; Chung DJ; Hassoun H; Lendvai N; Landgren O; Giralt S; Chari A; Jagannath S; Koehne G
Biol Blood Marrow Transplant; 2016 Feb; 22(2):258-267. PubMed ID: 26325439
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma.
Danylesko I; Shimoni A; Nagler A
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S330-48. PubMed ID: 24290219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]